## 1 SARS-CoV-2 infection- induced seroprevalence among

# 2 children and associated risk factors during pre- and

**3 omicron-dominant wave, from January 2021 through** 

## 4 November 2022, Thailand: Longitudinal study

- 5
- 6 Nungruthai Suntronwong<sup>1</sup>, Preeyaporn Vichaiwattana<sup>1</sup>, Sirapa Klinfueng<sup>1</sup>, Jiratchaya Puenpa<sup>1</sup>,
- 7 Sitthichai Kanokudom<sup>1,2</sup>, Suvichada Assawakosri<sup>1,2</sup>, Jira Chansaenroj<sup>1</sup>, Donchida Srimuan<sup>1</sup>,
- 8 Thaksaporn Thatsanatorn<sup>1</sup>, Siriporn Songtaisarana<sup>1</sup>, Natthinee Sudhinaraset<sup>1</sup>, Nasamon
- 9 Wanlapakorn<sup>1</sup>, Yong Poovorawan<sup>1,3\*</sup>
- <sup>1</sup>Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University,
- 11 Bangkok 10330, Thailand
- <sup>12</sup> <sup>2</sup> Center of Excellence in Osteoarthritis and Musculoskeleton, Faculty of Medicine,
- 13 Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society,
- 14 Bangkok, 10330, Thailand
- <sup>3</sup> The Royal Society of Thailand (FRS(T)), Sanam Sueapa, Dusit, Bangkok 10330, Thailand.
- 16
- 17 \*Corresponding author
- 18 Email: yong.p@chula.ac.th
- 19

## 21 Abstract

#### 22 Background

23	Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection can be
24	asymptomatic in young children. Therefore, the true rate of infection is likely underestimated.
25	Few data are available on the rate of infections in young children, and studies on the SARS-
26	CoV-2 seroprevalence among children during omicron wave are limited. Our study aims to
27	assess the SARS-CoV-2 infection-induced seroprevalence among children and estimated the
28	associated risk factors for seropositivity.
29	Methods
30	A longitudinal serological survey was conducted from January 2021 through November
31	2022. Samples were tested for anti-nucleocapsid (N) IgG, anti-receptor binding domain (RBD)
32	IgG using a chemiluminescent microparticle immunoassay (CMIA) and detected anti-RBD
33	Immunoglobulin (Ig) using an electrochemiluminescence immunoassay (ECLIA). The
34	vaccination and SARS-CoV-2 infection history were collected.
35	Results
36	A total of 452 serum samples were obtained from 249 children aged 5–7 years old who
37	were annually followed-up in the longitudinal serological survey. Of these, 191 participants
38	provided samples at two serial time points, including during the pre-and omicron dominant
39	wave. Overall, seroprevalence induced by SARS-CoV-2 infection was increased from 9.1%
40	(95%CI: 0.6-12.6%) during the pre-omicron wave to 49.7% (95%CI: 35.9-66.8%) during the
41	omicron wave. Amongst seropositive individuals, the infection-induced seroprevalence was

42 lower in vaccinated participants than those with no vaccination (40.4% vs. 57.4%; risk ratio,

43	0.71; 95%CI: 0.52–0.95). Nevertheless, the ratio of seropositive cases per recalled infection was
44	1.56 during the omicron dominant wave. In addition, overall seroprevalence induced by
45	infection, vaccination and hybrid immunity was 76.6% (151/197; 95%CI: 54.6-97.9%) between
46	January and November 2022.
47	
48	Conclusions
49	our study reports an increase in infection-induced seroprevalence among children during
50	the omicron wave. These findings highlight that estimating seroprevalence is crucial to monitor
51	SARS-CoV-2 exposure, particularly in asymptomatic infection, and help to optimize public
52	health policies and determine the effect of immunization in the pediatric population.
53	
54	Keywords: SARS-CoV-2, Seroprevalence, Children, Omicron variant
55	
56	
57	
58	
59	
60	
61	
62	
63	
64	
65	

## 66 Introduction

67	Most children with SARS-CoV-2 infection are asymptomatic at presentation. Thus,
68	mildly symptomatic and asymptomatic children might not be tested for or diagnosed with SARS-
69	CoV-2 infection [1]. As a result, pediatric COVID-19 cases are underestimated and likely higher
70	than reported according to the reverse transcriptase-polymerase chain reaction (RT-PCR) results.
71	Furthermore, children are commonly infected after close contact with other members in the same
72	household. They are likely unaware of their infection status, potentially contributing to virus
73	transmission [2].
74	Although children with COVID-19 typically develop a milder illness than adults, long-
75	term complications including multisystem inflammatory syndrome in children (MIS-C) can
76	occur after SARS-CoV-2 infection [3]. Recent evidence notes that COVID-19 vaccination in
77	children is associated with a high level of protection against MIS-C and a reduced rate of
78	hospitalization and deaths [4]. In Thailand, the Thai Food and Drugs Administration have
79	approved BNT162b2 for vaccination in children aged 5-11 years old, and CoronaVac and
80	BBIBP-CorV for children aged $\geq 6$ years old. Consequently, data on seroprevalence in children is
81	essential to inform and guide vaccine policies.
82	The value of a serological survey is the retrospective detection of individuals who had a
83	previous infection, even in an asymptomatic case, which helps monitor virus transmission [5].
84	Anti-nucleocapsid (N) and anti-receptor binding domain (RBD) antibodies are elicited after
85	natural infection or vaccination. However, anti-N antibodies can detect after receipt the
86	inactivated vaccine but not detected after receipt of the virus vector or mRNA vaccines.

87 Moreover, some Thai children could elicit anti-N IgG because of being vaccinated with an

88 inactivated vaccine. Consequently, the detection of anti-N and anti-RBD antibodies in

89	unvaccinated individuals and anti-N antibodies in vaccinated individuals with mRNA vaccines
90	could estimate the proportion of individuals who have been infected with SARS-CoV-2. In
91	addition, serological surveys can inform the impact of immunization on the population.
92	Omicron was first detected in Thailand in mid-December 2021. The incidence of omicron
93	infection rapidly increased and subsequently became the predominant variant by January 2022
94	[6]. Study demonstrated that the omicron variant is highly transmissible and can evade the
95	immune system even in vaccinated or previously infected individuals [7]. In line with this, the
96	spreading of omicron variants peaked between January and March 2022. In addition, infection by
97	the omicron variant resulted in milder symptoms and was associated with lower risks of
98	hospitalization and death than the delta variant [8]. However, few data are available on the rate
99	of infections in young children, and studies on the SARS-CoV-2 seroprevalence among children
100	during omicron wave are limited.
101	In this study, we assessed the seroprevalence of anti-SARS-CoV-2 antibodies induced by
102	SARS-CoV-2 infection from January 2021 to November 2022 (the duration spanned the pre- and
103	omicron wave) and estimated the associated risk factors for seropositivity. Data on
104	seroprevalence can help to estimate the number of children who experience SARS-CoV-2
105	infection and assess the impact of immunization on protect SARS-CoV-2 infection in pediatric
106	population which is paramount to establish public health prevention and vaccination strategies.
107	
108	

109

# 110 Materials and methods

#### 111 Study design and sample collection

112 This study analyzed the serum samples from children who were followed-up in the 113 longitudinal serological study of pertussis vaccine immunity at the Center of Excellence in 114 Clinical Virology, Chulalongkorn Memorial Hospital, Bangkok, Thailand, from January 1, 2021 115 through November 9, 2022 [9]. Participants were invited to complete surveys on SARS-CoV-2 116 infection and COVID-19 vaccination. This survey included questions regarding previous SARS-117 CoV-2 infections detected by RT-PCR test or antigen test kit (ATK); date of infection; and 118 vaccination data, including type, dose, and date of vaccination, as reported by the children's 119 parents. The survey responses were retrospectively collected between May and November 2022. 120 The inclusion criteria were the same as the longitudinal serological study of the pertussis vaccine 121 immunity. However, the exclusion criteria were parents who did not want to disclose vaccination 122 and infection history, and children who previously received any dose of the inactivated COVID-123 19 vaccine, because such individuals could elicit anti-N IgG from the inactivated vaccine. 124 The Research Ethics Committee of the Faculty of Medicine, Chulalongkorn University 125 approved the study (IRB number: 173/63). The study protocol adhered to the tenets of the 126 Declaration of Helsinki and Good Clinical Practice principles. Written informed consent was 127 obtained from the parents or legal guardians of all participating children.

128

#### 129 Serological analysis

130 Sera samples collected from eligible participants were subjected to IgG-specific testing

131 against SARS-CoV-2 nucleocapsid (N) protein using a chemiluminescent microparticle

132 immunoassay (CMIA) (Abbott Architect Immunoassay; Abbott Diagnostics, Abbott Park, IL,

133 USA). According to the manufacturer's instructions, we considered samples with a signal-to-cut-

134	off ratio $\geq 1.4$ as anti-N IgC	i positive, v	while samples	with a value <	1.4 was considered as
-----	------------------------------------	---------------	---------------	----------------	-----------------------

- 135 seronegative. The total immunoglobulin (Ig) and IgG specific against SARS-CoV-2 receptor
- 136 binding domain (RBD) quantitatively measured using the Roche Elecsys anti-SARS-CoV-2
- 137 immunoglobulin immune assay (Roche) and SARS-CoV-2 Quant IgG II (Abbott Diagnostics,
- 138 Abbott Park, IL, USA), respectively. Antibody level is expressed as U/mL for anti-RBD Ig, with
- 139 a cut-off  $\geq 0.8$  defined as positive and BAU/mL for anti-RBD IgG, with values  $\geq 7.1$  scored
- 140 positive.
- 141

#### 142 Classify the samples with seropositivity

143Infection-induced seropositivity was estimated based on the presence of anti-RBD Ig ( $\geq$ 1440.8 U/mL), anti-RBD IgG ( $\geq$ 7.1 BAU/mL) or anti-N IgG ( $\geq$  1.4 S/C) among unvaccinated145children and the presence of anti-N IgG or having an evidence of SARS-CoV-2 infection during146omicron variants in vaccinated individuals with BNT162b2 vaccine. Vaccination status was147classify according to the dates of reported infection and vaccination. Overall seroprevalence148induced by infection, vaccination, and hybrid immunity was estimated based on the anti-RBD149antibody seropositivity in both unvaccinated and vaccinated participants.

150

#### 151 Statistical analysis

Data are mainly presented as numbers and percentages. The primary outcome was infection-induced seroprevalence. Risk ratios associated with infection-induced seropositivity and demographic characteristics were calculated using the chi-square test. The ratio of children with infection-induced seropositivity during the omicron dominant wave per recalled of previous SARS-CoV-2 infection were assessed. Statistical analysis was conducted using SPSS v23.0

(IBM Corp, Armonk, NY, USA). A *p*-value <0.05 was considered to indicate statistically</li>
significant differences.

159

### 160 **Results**

#### 161 Study participants

162 There were 452 samples from 249 participants enrolled in the source study (Fig 1). Of 163 these, 241 samples were collected from January through December 2021 (hereafter referred to as 164 the pre-omicron wave), and 211 samples were collected from January to November 2022 165 (hereafter referred to as the omicron-dominant wave). Between January and November 2022, 166 two participants were excluded because they lacked vaccination history, and 12 participants were 167 excluded because they received an inactivated vaccine. Thus, 438 serum samples from 247 168 participants were eligible and met the criteria for the final analysis. In total, 438 samples were obtained, including 55% (241/438) serum samples collected 169 170 between January and December 2021 and 45% (197/438) collected between January and 171 November 2022, during which time omicron was predominantly circulating. The mean (SD) age 172 of study participants enrolled during pre- and omicron wave was 5.12(0.34) and 6.16(0.36)173 years old, and there were 51% female and 49% male subjects (S1 Table). Of these, 191 174 participants provided samples at two serial time points, including during the pre-and omicron 175 dominant wave, and the median interval between the two blood samplings was 362 days (IOR: 176 343–376). During the omicron-dominant wave, 45.2% (89/197) of participants received at least one dose of BNT162b2 by February 2022 included 42.7% (38/89), 55.1% (49/89) and 2.2% 177 178 (2/89) of participants who had been received a single dose, two-doses and three doses of

BNT162b2, respectively, while no participant enrolled during the pre-omicron wave received theCOVID-19 vaccine.

181

#### 182 Seroprevalence induced by SARS-CoV-2 infection

183 There were 120 samples out of a total of 438 that tested anti-RBD Ig or anti-N IgG

184 seropositive for unvaccinated participants and anti-N IgG seropositive or having reported of

185 SARS-CoV-2 infection during omicron for vaccinated participants, resulting in an estimated

186 infection-induced seroprevalence of 27.4% (95%CI: 15.7–40.3%) (Fig 2). The infection-induced

187 seroprevalence increased from 9.1% (95%CI: 0.6–12.6%) for January to December 2021 to

188 49.7% (95%CI: 35.9–66.8%) observed between January and November 2022. Amongst

189 seropositive participants during the pre-omicron wave, 14 participants were follow-up the

serological cohorts during the omicron-dominant wave and 87.5 % (14/16) of children were

191 provided evidence of re-infection.

192

#### 193 Factors associated with infection-induced seropositivity

Among unvaccinated participants, samples collected during the omicron dominant wave were more likely seropositive than those collected during the pre-omicron wave (57.4% vs.

196 9.1%; risk ratio, 6.29; 95%CI: 4.09–9.67, p<0.001) (Table 1). Notably, vaccinated participants

197 was less likely infected with SARS-CoV-2 than unvaccinated participants (40.4% vs. 57.4%; risk

ratio, 0.71; 95%CI: 0.52–0.95; p<0.05) and participants vaccinated with two-doses of BNT162b2

- 199 were associated with a low seroprevalence than those immunized with a single dose (24.5% vs.
- 200 63.2%; risk ratio, 0.39; 95%CI: 0.22–0.67, p<0.001). There was no difference in seroprevalence
- 201 rate between participants living in a household with  $\geq$ 5 members and those living in a household

- 202 with <5 members during the omicron wave. However, children living with household members
- 203 who had previous COVID-19 infection had a higher risk of seropositivity than those living with
- 204 household members without SARS-CoV-2 infection (73.7% vs.21.1%; risk ratio, 3.45; 95%CI:
- 205 2.19–5.55; P<0.001).
- 206
- 207 **Table 1.** SARS-CoV-2 infection-induced seropositivity and risk factors for seropositivity.

Characteristic	Overall	Infection-induced		Risk ratio associated with
		seroprevalence		seropositivity,
	n	n	(%)	Risk ratio (95%CI)
Overall	438	120	27.4%	-
-Pre-omicron wave	241	22	9.1%	Ref
-Omicron dominant wave	197	98	49.7%	5.45 (3.57-8.31)***
Sex, n (%) according to the study				
period				
Pre-omicron wave				
Boy	117	12	10.3%	Ref
Girl	124	10	8.1%	0.79 (0.35–1.75)
Omicron-dominant wave				
Boy	96	49	51.0%	Ref
Girl	101	49	48.5%	0.95 (0.72–1.26)

Vaccination status according to				
dates of infection and				
vaccination				
Unvaccinated				
Pre-omicron wave	241	22	9.1%	Ref
Omicron-dominant wave	108	62	57.4%	6.29 (4.09–9.67) ***
Omicron dominant wave				
(n=197)				
Unvaccinated	108	62	57.4%	Ref*
Vaccination	89	36	40.4%	0.71 (0.52–0.95)
Dose of vaccine				
-BNT162b2 (1 dose)	38	24	63.2%	Ref
-BNT162b2 (2 doses)	49	12	24.5%	0.39 (0.22–0.67)***
-BNT162b2 (3 doses)	2	0	0%	-
Pre-omicron wave				
Number of household members,				
n				
2-4	96	4	4.2%	Ref
≥5	62	12	19.4%	4.65 (1.57-13.76)**

N/A	83	6	7.2 %	-
Omicron-dominant wave				
Number of household members,				
n				
2–4	100	50	50.0%	Ref
$\geq 5$	64	35	54.7%	1.01 (0.81–1.47)
N/A	33	13	39.4%	-
Confirmed COVID-19 infection				
in household members tested via				
PCR or ATK during the omicron				
wave, n				
No	71	15	21.1%	Ref
Yes	95	70	73.7%	3.45 (2.19–5.55)***
N/A	31	13	41.9%	-

Statistical analysis was performed using the chi-square test. \* indicates p<0.05, \*\*\*indicates</li>
p<0.001\*\*\*indicates p<0.001.</li>

210

#### 211 Infection-induced seropositivity associated with previous SARS-CoV-2 testing

212 We further estimated the ratio of infection-induced seropositive cases per recalled

213 infection during the omicron dominant wave. Overall, 89.4% (176/197) participants completed a

survey on infection history. Subsequently, 92 of 176 children showed infection-induced

seropositivity. Of these, 64.1% (59/92) previously reported SARS-CoV-2 infection, and the

216	median interval between dates of infection and blood collection was 95 days	(IQR: 64–175),
-----	---	----------------

- 217 while 35.9% (33/92) reported being unaware of their infection status (Table 2). Therefore, the
- 218 ratio of infection-induced seropositive cases per recalled infection during omicron was 1.56
- 219 (92/59). Moreover, only 4.3% (4/94) seronegative participants reported previous SARS-CoV-2
- 220 infection, for which the median interval between infection and blood collection dates was 311
- 221 days (IQR: 272.5–316.5).
- 222

```
223 Table 2 Association between infection-induced seropositivity and previous SARS-CoV-2
```

infection. Number of children who complete a survey of infection history (n=176) and infection-

induced seropositivity during the omicron-dominant wave (January–November 2022).

	Infection-induced	Infection-induced
	seropositive (n=92)	seronegative (n=94)
History of previous infection (n=63)	59	4
Interval between the reported date of infection and blood collection, median (IQR)	95 (64–175)	311 (272.5–316.5)
No history of previous infection (n=113)	33	80

227 Previous SARS-CoV-2 infection was diagnosed by RT-PCR or ATK test

228

#### 229 Seroprevalence induced by infection, vaccination and hybrid

#### 230 immunity

We further estimated the overall seroprevalence induced by natural infection, vaccination and hybrid immunity based on the seropositivity of anti-RBD antibodies (Fig 3). Regarding the vaccine implementation in children, the seropositivity of anti-RBD antibodies was 76.6% (151/197; 95%CI: 54.6-97.9%) between January and November 2022 which increased by Mar 2022 and reached greater than 80% (95%CI: 88.6-96.2%) since April 2022.

236

## 237 **Discussion**

Our findings report the increase in seroprevalence induced by infection among children from January through November 2022, indicating the high rates of SARS-CoV-2 infection during the omicron wave. This is in agreement with other studies that have reported a significant rise in the seroprevalence rate among children during the omicron wave in South Africa [10] and the United States [11]. This finding supported the previous report which showed that the omicron variant is more transmissible than the previous SARS-CoV-2 variants [7].

Our results also showed that even children who received the BNT162b2 vaccine were anti-N IgG seropositive during the omicron wave. This result might be related to the antibody evasion by omicron variants and the limit of vaccine efficacy among children [12]. Although vaccinated children were susceptible to being infected by the omicron variant, the risks of infection and hospitalization were reduced for vaccinated compared to unvaccinated children

aged between 5 and 11 years [13]. In addition, our study showed that vaccinated children with
two-dose vaccines were less likely to be seropositive than those who were vaccinated with a
single dose. This result was supported by a meta-analysis study that suggested that the estimated
mean secondary attack rates observed during the omicron wave were higher in partially
vaccinated cases (76.8%, 95%CI: 7.7%–99.2%) than in fully vaccinated cases (50.8%, 95%CI:
47.9%–53.8%) [14].

Although an increased number of household members did not affect the risk of seropositivity in children, we found a higher risk of seropositivity was observed in children living with infected household members than those living with non-infected household members. This finding was consistent with a study from Switzerland that indicated the risk of being seropositive in children aged <6 years was more likely associated with the number of household members who tested positive for SARS-CoV-2, indicating the SARS-CoV-2 transmission for children aged <6 years occurs commonly within the family [15].

The proportion of anti-N IgG or anti-RBD antibody seropositive among unvaccinated and 262 263 anti-N IgG seropositive among vaccinated cases may reflect the true rate of infections, including 264 mildly symptomatic or asymptomatic cases and undetected by COVID-19 testing. Our study 265 found that 35.9% children aged 5–7 years with seropositivity reported no previous infection. 266 This result may reflect either asymptomatic infection or undetected infection upon COVID-19 267 testing in patients likely unaware of their infection status, in which case the virus remains 268 actively transmissible [16]. In addition, our estimated ratio of seropositive cases per recall 269 infection was lower than that reported in a seroprevalence study in children aged 3–11 years 270 from Germany between March and May 2021 (1.56 vs. 3.0) [17] and another study of awareness 271 in adults during the omicron wave (1.56 vs. 2.28) [5].

272	The anti-N IgG seronegative results in children that reported infection may be owing to
273	the long interval from infection to blood sampling and the severity of disease after infection. This
274	result was supported by a previous study in adults indicating that 87.5% individuals had
275	detectable the anti-N IgG even 3 months post-infection, while only 26.6% individuals had
276	detectable the anti-N IgG 12 months post-infection [18]. In addition, recent evidence showed that
277	the sensitivity of anti-N IgG detection among individuals with recent infection defined by RT-
278	PCR testing ranged from 74% to 81% during the omicron wave [19]. To overcome the limitation
279	of anti-N IgG detection, our study included anti-RBD antibodies to classify the seropositivity
280	induced by SARS-CoV-2 infection in unvaccinated participants and be considered evidence of
281	SARS-CoV-2 infection in vaccinated participants.
282	The limitations of the study include the small sample size, as this may not represent the

seroprevalence in the general population. Further, the present study could have underestimated the cumulative seropositivity because children with inactivated vaccines were not included. Furthermore, anti-N antibody titers waned over time, and the sensitivity of the anti-N IgG assay to detect the antibody was dependent on the time between the infection and blood collection and vaccination status [20].

In conclusion, our study reports an increase in infection-induced seroprevalence among children during the omicron wave and overall seroprevalence induced by natural infection, vaccination and hybrid immunity. This shows that the benefit of anti-SARS-CoV-2 antibody detection can help to assess the seroprevalence induced by infection which subsequently track the transmission of SARS-CoV-2 variants and determine the effect of immunization in the pediatric population.

295	<b>Acknowledgments:</b>	We would	like to that	nk all the st	aff of the	Center of E	Excellence in	Clinical

- 296 Virology. This research was financially supported by the Health Systems Research Institute
- 297 (HSRI), National Research Council of Thailand (NRCT), the Center of Excellence in Clinical
- 298 Virology, Chulalongkorn University, and King Chulalongkorn Memorial Hospital, MK
- 299 Restaurant Group Aunt Thongkam Foundation, BJC Big C Foundation, and the Second Century
- 300 Fund (C2F), Chulalongkorn University.

301

- 302 Author Contributions: Conceptualization, N.S.(Nungruthai Suntronwong), N.W. and Y.P.; data
- 303 curation, N.S. (Nungruthai Suntronwong), J.P., D.S., T.T., S.S., and N.S. (Natthinee
- 304 Sudhinaraset); formal analysis, N.S.(Nungruthai Suntronwong); methodology, P.V., S.K. (Sirapa
- 305 Klinfueng), S.K. (Sitthichai Kanokudom), S.A., and J.C.; project administration, Y.P.; writing-
- 306 original draft, N.S. (Nungruthai Suntronwong); writing-review and editing, N.S. (Nungruthai
- 307 Suntronwong), S.K. (Sitthichai Kanokudom), N.W., and Y.P. All authors have read and agreed
- 308 to the published version of the manuscript.

309

#### 310 Financial Disclosure

311 This work was supported by the National Research Council of Thailand, the Health Systems

- 312 Research Institute, the Center of Excellence in Clinical Virology of Chulalongkorn
- 313 University, King Chulalongkorn Memorial Hospital, and the Berli Jucker Company Big C
- 314 foundation. Nungruthai Suntronwong reports that financial support was also provided by the
- 315 Second Century Fund Fellowship of Chulalongkorn University. The funders had no role in study
- 316 design, data collection and analysis, decision to publish, or preparation of the manuscript.

318	Institu	tional Review Board Statement: The study protocol was approved by the Research
319	Ethics	Committee of the Faculty of Medicine, Chulalongkorn University (IRB number: 173/63).
320	The stu	udy protocol adhered to the tenets of the Declaration of Helsinki and Good Clinical
321	Practic	e principles. Written informed consent was obtained from the parents or legal guardians of
322	all part	ticipating children.
323		
324	Data A	Availability Statement: All relevant data are within the manuscript and its Supporting
325	Inform	ation files.
326		
327	Declar	cation of Competing Interests: The authors have declared that no competing interests exist.
328		
329	Refe	erences
330	1.	Karron RA, Hetrich MK, Na YB, Knoll MD, Schappell E, Meece J, et al. Assessment of
331		Clinical and Virological Characteristics of SARS-CoV-2 Infection Among Children
332		Aged 0 to 4 Years and Their Household Members. JAMA Netw Open
333		2022;5(8):e2227348. Doi: 10.1001/jamanetworkopen.2022.27348.
334	2.	Stein-Zamir C, Abramson N, Shoob H, Libal E, Bitan M, Cardash T, et al. A large
335		COVID-19 outbreak in a high school 10 days after schools' reopening, Israel, May 2020.
336		Euro Surveill 2020;25(29):2001352. Doi: 10.2807/1560-7917.ES.2020.25.29.2001352.
337	3.	Pierce CA, Herold KC, Herold BC, Chou J, Randolph A, Kane B, et al. COVID-19 and
338		children. Science 2022;377(6611):1144-1149. Doi: 10.1126/science.ade1675.
339	4.	Zambrano LD, Newhams MM, Olson SM, Halasa NB, Price AM, Boom JA, et al.
340		Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem

341		Inflammatory Syndrome in Children Among Persons Aged 12-18 Years – United States,
342		July-December 2021. MMWR Morb Mortal Wkly Rep 2022;71(2):52-58. Doi:
343		10.15585/mmwr.mm7102e1.
344	5.	Joung SY, Ebinger JE, Sun N, Liu Y, Wu M, Tang AB, et al. Awareness of SARS-CoV-2
345		Omicron Variant Infection Among Adults With Recent COVID-19 Seropositivity. JAMA
346		Netw Open 2022;5(8):e2227241. Doi: 10.1001/jamanetworkopen.2022.27241.
347	6.	Puenpa J, Rattanakomol P, Saengdao N, Chansaenroj J, Yorsaeng R, Suwannakarn K et
348		al. Molecular characterization and tracking of the severe acute respiratory syndrome
349		coronavirus 2, Thailand, 2020–2022. Research Square 2022. Doi:
350		https://doi.org/10.21203/rs.3.rs-1545056/v1.
351	7.	Jalali N, Brustad HK, Frigessi A, MacDonald EA, Meijerink H, Feruglio SL, et al.
352		Increased household transmission and immune escape of the SARS-CoV-2 Omicron
353		compared to Delta variants. Nat Commun 2022;13(1):5706. Doi: 10.1038/s41467-022-
354		33233-9.
355	8.	Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes
356		associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2
357		subvariant infection in Southern California. Nat Med 2022;28(9):1933-1943. Doi:
358		10.1038/s41591-022-01887-z.
359	9.	Wanlapakorn N, Maertens K, Vongpunsawad S, Puenpa J, Tran TMP, Hens N, et al.
360		Quantity and Quality of Antibodies After Acellular Versus Whole-cell Pertussis Vaccines
361		in Infants Born to Mothers Who Received Tetanus, Diphtheria, and Acellular Pertussis
362		Vaccine During Pregnancy: A Randomized Trial. Clin Infect Dis 2020;71(1):72-80. Doi:
363		10.1093/cid/ciz778.

364	10. Madhi SA, Kwatra G, Myers JE, Jassat W, Dhar N, Mukendi CK, et al. Population
365	Immunity and Covid-19 Severity with Omicron Variant in South Africa. N Engl J Med
366	2022;386(14):1314-1326. Doi: 10.1056/NEJMoa2119658.
367	11. Clarke KEN, Jones JM, Deng Y, Nycz E, Lee A, Iachan R, et al. Seroprevalence of
368	Infection-Induced SARS-CoV-2 Antibodies – United States, September 2021-February
369	2022. MMWR Morb Mortal Wkly Rep 2022;71(17):606-608. Doi:
370	10.15585/mmwr.mm7117e3.
371	12. Katz SE, Edwards K. Protecting Children Against Omicron. JAMA 2022;327(22):2195-
372	2197. Doi: 10.1001/jama.2022.7315.
373	13. Dorabawila V, Hoefer D, Bauer UE, Bassett MT, Lutterloh E, Rosenberg ES. Risk of
374	Infection and Hospitalization Among Vaccinated and Unvaccinated Children and
375	Adolescents in New York After the Emergence of the Omicron Variant. JAMA
376	2022;327(22):2242-2244. Doi: 10.1001/jama.2022.7319.
377	14. Madewell ZJ, Yang Y, Longini IM Jr, Halloran ME, Dean NE. Household Secondary
378	Attack Rates of SARS-CoV-2 by Variant and Vaccination Status: An Updated
379	Systematic Review and Meta-analysis. JAMA Netw Open 2022;5(4):e229317. Doi:
380	10.1001/jamanetworkopen.2022.9317.
381	15. Rouge Elton PA, Schmitt PA, Faouzi M, Zimmermann P, Ritter Schenk C.
382	Seroprevalence of SARS-CoV-2 antibodies and associated risk factors in children less
383	than 6 years of age in the canton of Fribourg, Switzerland (COVPED study): a
384	population-based cross-sectional study. Swiss Med Wkly 2022;152:w30173. Doi:
385	10.4414/smw.2022.w30173.

386	16. Kim EY, Choe YJ, Park H, Jeong H, Chung JH, Yu J, et al. ommunity Transmission of
387	SARS-CoV-2 Omicron Variant, South Korea, 2021. Emerg Infect Dis. 2022
388	Apr;28(4):898-900. Doi: 10.3201/eid2804.220006.
389	17. Sorg AL, Bergfeld L, Jank M, Corman V, Semmler I, Goertz A, et al. Cross-sectional
390	seroprevalence surveys of SARS-CoV-2 antibodies in children in Germany, June 2020 to
391	May 2021. Nat Commun 2022;13(1):3128. Doi: 10.1038/s41467-022-30482-6.
392	18. Chansaenroj J, Yorsaeng R, Posuwan N, Puenpa J, Wanlapakorn N, Sudhinaraset N, et al.
393	Long-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered
394	COVID-19 patients. Sci Rep 2021;11(1):23216. Doi: 10.1038/s41598-021-02659-4.
395	19. Erikstrup C, Laksafoss AD, Gladov J, Kaspersen KA, Mikkelsen S, Hindhede L, et al.
396	Seroprevalence and infection fatality rate of the SARS-CoV-2 Omicron variant in
397	Denmark: A nationwide serosurveillance study. Lancet Reg Health Eur 2022;21:100479.
398	Doi: 10.1016/j.lanepe.2022.100479.
399	20. Asamoah-Boaheng M, Goldfarb DM, Barakauskas V, Kirkham TL, Demers PA, Karim
400	ME, et al. Evaluation of the Performance of a Multiplexed Serological Assay in the
401	Detection of SARS-CoV-2 Infections in a Predominantly Vaccinated Population.
402	Microbiol Spectr 2022;10(1):e0145421. Doi: 10.1128/spectrum.01454-21.
403	
404	
405	
406	
407	
408	

## 409 Figures legends

- 410 Figure 1 Recruitment of participants.
- 411

#### 412 Figure 2 Monthly distribution of SARS-CoV-2 variants and infection-induced

- 413 seroprevalence. SARS-CoV-2 infection-induced seropositivity was identified by the
- 414 seropositivity of anti-N IgG or anti-RBD antibody for unvaccinated individuals and anti-N IgG
- 415 seropositivity or having reported of SARS-CoV-2 infection for vaccinated individuals with
- 416 BNT162b2 vaccine. Sera samples were collected from Thai children between January 2021 and
- 417 November 2022. Data on SARS-CoV-2 variants circulating during the study period was obtained
- 418 from a previous report [6]. The stacked bar graph represents the percentage of infection-induced
- 419 seropositivity according to vaccination status (see left Y-axis). Color shaded areas indicate the
- 420 number of positive samples of SARS-CoV-2 variants (see right Y -axis). The vertical dotted
- 421 lines indicate the quarter.
- 422

423 Figure 3 Monthly distribution of seroprevalence induced by infection, vaccination, and

424 hybrid immunity observed in children aged 5-7 years old between January 2021 and

425 November 2022. Seroprevalence induced by infection, vaccination, and hybrid immunity was
426 estimated based on the anti-RBD antibody seropositivity in both unvaccinated and vaccinated
427 participants.

428

### 429 Supplementary Information

#### 430 S1 Table. Baseline characteristics and data summaries of vaccination status and

- 431 infection history. The final study participants recruited from January to December 2021 (pre-
- 432 omicron wave) and January to November 2022 (omicron-dominant wave). Sera samples were
- 433 categized according to the dates of blood collection into pre- and omicron dominant wave.
- 434 Vaccination status was classify according to the dates of reported infection and vaccination.



# Figure1



# Figure2



# Figure3